Kyowa Hakko Bio is selling its amino acid businesses, including Cape Girardeau's BioKyowa facility, to China's MEIHUA. The transition promises job stability and unchanged production levels for the U.S ...

The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo ...

The drug is manufactured by Japanese firm Kyowa Hakko Kirin (Kyowa Kirin), and is for adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior ...

Kyowa Kirin ploughed ahead with KW-6356 despite the reservations of its former partner Lundbeck, which held the rights to KW-6356 outside Asia before handing them back to the Japanese company.

JPMorgan initiated coverage on Kirin Holdings Co Ltd (2503:JP) (OTC: KNBWY), assigning a Neutral rating to the company's shares and establishing a price target of ¥2,100. The move comes as the analyst ...

The enhanced partnership provides enterprise-wide access to AlphaMeld Corporation’s proprietary AI-powered AlphaMeld ® platform, further accelerating Kyowa Kirin’s innovative drug discovery ...

The Japanese pharmaceutical company Kyowa Kirin Co. plans to sell shares in the Chinese division of the Hong Kong company WinHealth Pharma Group Co. for 15 billion yen ($100 million) as part of the ...

Morgan Stanley (NYSE:MS) updated its outlook on Kirin Holdings Co Ltd (2503:JP) (OTC: KNBWY), raising the company's price target from ¥2,200 to ¥2,250, while sustaining an Equalweight rating on the ...

Aa Aaaaaaaaa Aaa 430.57 +21.55% ...